DEA Notice: Janssen Pharmaceuticals Applies to Import Controlled Substances
Estimated reading time: 2–3 minutes
Date: January 8, 2026
Who applied:
Janssen Pharmaceuticals Inc. applied to be registered as an importer of specific controlled substances.
Address:
1440 Olympic Drive, Buildings 1-5 & 7-14, Athens, Georgia 30601-1645.
Controlled Substances Requested:
- Ethylphenidate (Drug code: 1727, Schedule I)
- Methylphenidate (Drug code: 1724, Schedule II)
Purpose:
Janssen plans to import these substances only for analytical purposes. No other activities involving these drug codes are permitted under this registration.
Regulatory Information:
- The application follows 21 CFR 1301.34(a).
- Permit approvals will happen only if the business activity fits U.S. law, specifically 21 U.S.C. 952(a)(2).
- The permission does not allow the import of finished drugs, whether FDA-approved or not, for sale.
Comments and Hearings:
- Registered bulk manufacturers and applicants can submit electronic comments or objections by February 9, 2026.
- Requests for a hearing about the application must be submitted by February 9, 2026.
- Comments must be made at https://www.regulations.gov.
- Hearing requests must be sent to the DEA at 8701 Morrissette Drive, Springfield, Virginia 22152, to the Attention of the Hearing Clerk/OALJ, DEA Federal Register Representative/DPW, and the Administrator.
Notice Published By:
Thomas Prevoznik, Deputy Assistant Administrator.
Document Number:
2026-00128
Date Filed:
January 7, 2026
For more information, visit the official Federal Register website.
Legal Disclaimer
This article includes content collected from the Federal Register (federalregister.gov). The content is not an official government publication. This article is for informational purposes only and does not constitute legal advice. For case-specific consultation, please contact us. Read our full Legal Disclaimer, which also includes information on translation accuracy.
